New pill aims to tame Huntington's: 400-Patient trial underway

NCT ID NCT07378644

Recruiting now Disease control Sponsor: Skyhawk Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 13 times

Summary

This study tests an oral medication called SKY-0515 in 400 adults aged 25 and older with Huntington's disease. The goal is to see if the drug can lower harmful proteins and improve movement, thinking, and daily function. Participants are randomly assigned to receive either the drug or a placebo, and researchers will track changes over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CINME Centro de Investigaciones Metabólicas
RECRUITING

Buenos Aires, C1056 AB, Argentina

Contact Phone: •••-•••-••••
PSEG Centro de Pesquisa Clinica
NOT_YET_RECRUITING

São Paulo, São Paulo, 04038002, Brazil

Contact Phone: •••-•••-••••
Pineo Medical Ecosystem
RECRUITING

Tbilisi, Georgia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Simon Khechinashvili University Hospital
RECRUITING

Tbilisi, Georgia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HUNTINGTON DISEASE